![Für diesen Artikel ist leider kein Bild verfügbar.](/img/platzhalter480px.png)
Campath - 1 H
Emerging Frontline Therapy in Chronic Lymphocytic Leukemia
Seiten
2001
CRC Press (Verlag)
978-1-84214-060-4 (ISBN)
CRC Press (Verlag)
978-1-84214-060-4 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
This is a detailed clinical reference on Campath-1H, which stands alone among monoclonal antibodies because its reciprocal antigen CD52 is expressed in diverse cell types, and its further potential for clinical practice in hemato-oncology in the treatment of B-cell chronic lymphocytic leukemia.
This is the only authoritative, detailed clinical reference on Campath-1H, which stands alone among monoclonal antibodies because its reciprocal antigen CD52 is expressed in diverse cell types, and its further potential for clinical practice in hemato-oncology in the treatment of B-cell chronic lymphocytic leukemia. It records the development and actions of Campath-1H, presents the unique clinical, immunological and molecular features of B-cell chronic lymphocytic leukemia, and explores the potential of Campath-1H as frontline therapy for patients with B-CLL. The book contains five main chapters on B-cell chronic lymphocytic leukemia, the road to remission (from single agent intervention to combination therapy and onward), monoclonal antibodies in cancer (the development of Campath-1H), Campath-1H in B-CLL (remissions of refractory disease), and the role of Campath-1H prior to bone marrow transplant in refractory B-CLL plus a concluding chapter on future perspectives.
This is the only authoritative, detailed clinical reference on Campath-1H, which stands alone among monoclonal antibodies because its reciprocal antigen CD52 is expressed in diverse cell types, and its further potential for clinical practice in hemato-oncology in the treatment of B-cell chronic lymphocytic leukemia. It records the development and actions of Campath-1H, presents the unique clinical, immunological and molecular features of B-cell chronic lymphocytic leukemia, and explores the potential of Campath-1H as frontline therapy for patients with B-CLL. The book contains five main chapters on B-cell chronic lymphocytic leukemia, the road to remission (from single agent intervention to combination therapy and onward), monoclonal antibodies in cancer (the development of Campath-1H), Campath-1H in B-CLL (remissions of refractory disease), and the role of Campath-1H prior to bone marrow transplant in refractory B-CLL plus a concluding chapter on future perspectives.
B-cell chronic lymphocytic leukemia: molecular basis and prognostic markers. The road to remission: from single agent intervention to combination therapy and onward. Monoclonal antibodies in cancer: the development of Campath-1H. Campath-1H in B-CLL: remission of refractory disease. The role of Campath-1H prior to bone marrow transplant in refractory B-CLL. Future perspectives. Index.
Erscheint lt. Verlag | 15.3.2001 |
---|---|
Verlagsort | London |
Sprache | englisch |
Gewicht | 494 g |
Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hämatologie |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
ISBN-10 | 1-84214-060-4 / 1842140604 |
ISBN-13 | 978-1-84214-060-4 / 9781842140604 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Hämatologie und Internistische Onkologie
Buch | Softcover (2023)
ecomed-Storck GmbH (Verlag)
129,99 €
Buch | Hardcover (2023)
Urban & Fischer in Elsevier (Verlag)
124,00 €